NYSE:ANVS Annovis Bio (ANVS) Stock Price, News & Analysis $0.71 -0.04 (-5.33%) Closing price 11/20/2026 03:59 PM EasternExtended Trading$0.73 +0.02 (+2.82%) As of 11/20/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Annovis Bio Stock (NYSE:ANVS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Annovis Bio alerts:Sign Up Key Stats Today's Range$0.70▼$0.7750-Day Range$0.65▼$1.3952-Week Range$0.62▼$5.50Volume1.43 million shsAverage Volume3.61 million shsMarket Capitalization$44.04 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company Overview Annovis Bio is a clinical-stage biotechnology company based in Malvern, Pennsylvania. Founded in 2008, the company researches and develops treatments for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. AI Generated. May Contain Errors. Read More Annovis Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreANVS MarketRank™: 3.56530898876 of 5 starsAnnovis Bio scored higher than 71% of companies evaluated by MarketBeat, and ranked 172nd out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingAnnovis Bio has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAnnovis Bio has a consensus price target of $10.00, representing about 1,308.5% upside from its current price of $0.71.Amount of Analyst CoverageAnnovis Bio has only been the subject of 2 research reports in the past 90 days.Read more about Annovis Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Annovis Bio are expected to grow in the coming year, from ($1.29) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Annovis Bio is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Annovis Bio is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted14.81% of the float of Annovis Bio has been sold short.Short Interest Ratio / Days to CoverAnnovis Bio has a short interest ratio ("days to cover") of 6.77.Change versus previous monthShort interest in Annovis Bio has recently decreased by 6.38%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnnovis Bio does not currently pay a dividend.Dividend GrowthAnnovis Bio does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.64 News SentimentAnnovis Bio has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Annovis Bio this week, compared to 1 article on an average week.Search Interest10 people have searched for ANVS on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Annovis Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $5,000,000.00 in company stock, which represents 11.3543% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Annovis Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,000,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders15.92% of the stock of Annovis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions15.83% of the stock of Annovis Bio is held by institutions.Read more about Annovis Bio's insider trading history. Receive ANVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annovis Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANVS Stock News HeadlinesAlzheimer's pill buntanetap: Annovis says FDA accepted pooled safety plan; efficacy unprovenNovember 20 at 10:52 PM | msn.comAnnovis Bio To Pool Safety Data From Four Buntanetap Studies Following FDA AgreementNovember 20 at 12:50 PM | rttnews.comPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access for just $7. The specialized indicator shows when a stock is likely to "snap back," helping traders avoid buying at the peak. It can also flag when a stock may bounce off the bottom so you can time your entry. Run NVDA or any other popular AI stock through it before you place a trade.November 22 at 1:00 AM | Base Camp Trading (Ad)FDA Agrees To Annovis Bio's Safety Data Integration Plan Ahead Of Buntanetap NDA; Stock UpNovember 20 at 12:50 PM | rttnews.comAnnovis Secures FDA Agreement on Integrated Summary of Safety Plan, Combining Alzheimer’s and Parkinson’s Data Ahead of Buntanetap NDANovember 20 at 12:50 PM | finance.yahoo.comAnnovis Secures FDA Agreement on Integrated Summary of Safety Plan, Combining Alzheimer's and Parkinson's Data Ahead of Buntanetap NDANovember 20 at 8:00 AM | globenewswire.comAnnovis Bio (NYSE:ANVS) Earns "Buy" Rating from Roth CapitalNovember 18, 2026 | americanbankingnews.comInsider Buying: Annovis Bio (NYSE:ANVS) Director Buys $5,000,000.00 in StockNovember 7, 2026 | insidertrades.comSee More Headlines ANVS Stock Analysis - Frequently Asked Questions How have ANVS shares performed this year? Annovis Bio's stock was trading at $3.43 at the start of the year. Since then, ANVS stock has decreased by 79.3% and is now trading at $0.71. How were Annovis Bio's earnings last quarter? Annovis Bio, Inc. (NYSE:ANVS) issued its quarterly earnings results on Friday, November, 13th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.08. When did Annovis Bio IPO? Annovis Bio (ANVS) raised $12 million in an initial public offering on Thursday, November 18th 2021. The company issued 2,000,000 shares at $6.00 per share. Who are Annovis Bio's major shareholders? Annovis Bio's top institutional shareholders include Marshall Wace LLP (3.95%), State Street Corp (0.24%), Empowered Funds LLC (0.08%) and StoneX Group Inc. (0.06%). Insiders that own company stock include Michael B Hoffman and Maria-Luisa Maccecchini. View institutional ownership trends. How do I buy shares of Annovis Bio? Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Annovis Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Annovis Bio investors own include NVIDIA (NVDA), Cassava Sciences (FLNA), Anavex Life Sciences (AVXL), Advanced Micro Devices (AMD), Micron Technology (MU), Dell Technologies (DELL) and Altimmune (ALT). Company Calendar Last Earnings11/13/2026Today11/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ANVS's financial health is in the Red zone, according to TradeSmith. ANVS has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:ANVS CIK1477845 Webwww.annovisbio.com Phone(484) 875-3192FaxN/AEmployees7Year Founded2008Price Target and Rating Average Price Target for Annovis Bio$10.00 High Price Target$17.00 Low Price Target$3.00 Potential Upside/Downside+1,308.5%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$28.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-8,315.60% Return on Assets-318.95% Debt Debt-to-Equity RatioN/A Current Ratio0.88 Quick Ratio3.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.21) per share Price / Book-3.38Miscellaneous Outstanding Shares62,023,000Free Float52,149,000Market Cap$44.04 million OptionableOptionable Beta1.36 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NYSE:ANVS) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.